Crohn's Disease (CD) Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The crohn's disease (CD) treatment market size has grown strongly in recent years. It will grow from $11.76 billion in 2024 to $12.38 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rising prevalence of crohn's disease, growing awareness of the disease, government initiatives, changing lifestyle.

The crohn's disease (CD) treatment market size is expected to see strong growth in the next few years. It will grow to $15.06 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn's disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.

The rising prevalence of inflammatory bowel diseases is expected to drive the growth of the Crohn's disease (CD) treatment market in the coming years. Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory conditions that primarily affect the gastrointestinal (GI) tract. Treatments for Crohn's disease (CD) help alleviate symptoms, reduce inflammation, encourage remission, and improve the overall quality of life for individuals affected by chronic inflammatory bowel disease. For example, in September 2023, the United States National Library of Medicine, a medical library based in the US, estimated that the incidence of IBD in Canada was 30 cases per 100,000 person-years in 2023, with projections showing a steady annual increase of about 0.58%. As of 2023, the prevalence of IBD in Canada reached approximately 825 per 100,000, with predictions indicating it could rise to 1.1% of the population by 2035. Thus, the growing prevalence of inflammatory bowel diseases is driving the demand for Crohn's disease (CD) treatments.

Anticipated growth in the Crohn's disease treatment market can be attributed to the increasing number of clinical trials. Clinical trials are crucial for assessing the safety and effectiveness of new therapies, potentially leading to regulatory approvals and the introduction of novel treatment options for Crohn's disease (CD) patients. The demand for more efficient CD treatments encourages clinical trials, driven by the desire of patients and healthcare providers for improved outcomes with reduced side effects, thereby stimulating research and development endeavors. For example, the University of California reported 17 ongoing clinical trials focused on vedolizumab, oral ozanimod, and the long-term efficacy of mirikizumab for pediatric CD and ulcerative colitis patients, highlighting the proliferation of clinical trials in the fie.

Leading companies in the Crohn's disease (CD) treatment market are focused on the introduction of innovative technologies like IBDSENSE to maintain their market position. An example of this is the development of IBDSENSE by The IRR Chemistry Hub, an interdisciplinary hub based in Scotland. IBDSENSE is designed to enhance the diagnosis and monitoring of inflammatory bowel diseases, including Crohn's disease, through non-invasive methods. The technology utilizes fluorescence-based techniques to measure the enzyme activity of Granzyme B (GzmB) in patient biosamples, aiming to enhance the patient experience and treatment options.

In June 2023, Merck & Co. Inc., a pharmaceutical company based in the United States, completed its acquisition of Prometheus Biosciences Inc. for a total of $10.8 billion. This strategic move by Merck & Co. is intended to broaden its range of products related to the treatment of immunological and inflammatory conditions. Prometheus Biosciences, a biotechnology company based in the United States, specializes in the development of drugs for inflammatory diseases, particularly in the areas of Crohn's disease and inflammatory bowel disease treatments.

Major companies operating in the crohn's disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn's disease (CD) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Crohn's disease (CD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Crohn's disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn's disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

The primary categories of drugs used in the treatment of Crohn's disease are antibiotics, aminosalicylates, corticosteroids, immunomodulators, and other types of medications. Antibiotics are drugs that combat bacterial infections by either killing the bacteria or inhibiting their growth and reproduction. These drugs can be administered orally or via injection, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The Crohn’s disease treatment market research report is one of a series of new reports that provides Crohn’s disease treatment market statistics, including Crohn’s disease treatment industry global market size, regional shares, competitors with a Crohn’s disease treatment market share, detailed Crohn’s disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the Crohn’s disease treatment industry. This Crohn’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.